

1 The VIPR-1 trial (Visualizing Ischemia in the Pancreatic Remnant) - Assessing the role of  
2 intraoperative indocyanine green perfusion of the transected pancreas in predicting postoperative  
3 pancreatic leaks: protocol for a phase II clinical trial.

4

5 Gustavo Salgado-Garza <sup>1</sup>, Annika Willy <sup>1</sup>, Flavio G. Rocha <sup>1,2,3</sup>, Skye C. Mayo <sup>1,2,3</sup>, Brett C.  
6 Sheppard <sup>1,2,3</sup>, Patrick J. Worth <sup>1,2,3,\*</sup>

7 <sup>1</sup> Oregon Health & Science University, Department of Surgery, Portland, OR, USA.

8 <sup>2</sup> Brenden Colson Center for Pancreatic Care, Oregon Health & Science University, Portland,  
9 OR, USA.

10 <sup>3</sup> Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.

11 \* Corresponding author

12 E-mail: [worth@ohsu.edu](mailto:worth@ohsu.edu)

13 Funding: This study is supported by a Medical Research Foundation of Oregon grant. The  
14 funders did not participate in the study design and will not be involved in data collection,  
15 analysis, or dissemination of results.

16 Competing interests: The authors have declared that no competing interest exists.

17 Data availability: Once the study is completed, relevant, deidentified data from this study will be  
18 available upon request.

19

20

## 21 **Abstract**

22 Surgery of the pancreas has come a long way since its inception; however, postoperative  
23 morbidity is still high. Pancreatic leaks and fistulas are common complications in patients  
24 undergoing surgery to remove the pancreas. Fistulas delay subsequent oncological care after  
25 surgery and prolong the hospital stay. Hypoperfusion to the pancreas has been characterized as  
26 one factor leading to fistulas. Indocyanine green (ICG) injection allows the surgeon to evaluate  
27 blood perfusion to tissue in real-time. This protocol describes a trial that aims to assess the  
28 effectiveness of intraoperative ICG metrics of the cut edge of the pancreas to predict  
29 postoperative fistulas. A single group will participate in an observational, surgeon-blinded, phase  
30 II trial. ICG measurements of the cut edge of the pancreas will be recorded before reconstruction.  
31 International Study Group on Pancreatic Surgery criteria for pancreatic fistula will be used to  
32 define leaks and fistulas. The primary outcome will be the correlation between ICG  
33 measurements and the development or absence of fistula formation. Currently, limited objective  
34 intraoperative predictors exist for predicting postoperative fistulas. Having a reliable predictive  
35 tool could decrease the healthcare burden posed by fistulas. The findings of this trial will provide  
36 conclusions on the usefulness of ICG measurements in predicting postoperative pancreatic  
37 fistulas and leaks. This clinical trial is registered in ClinicalTrials.gov with the ID  
38 NCT06084013. The current protocol version is v1.0.

## 39 **Introduction**

40 Pancreatic cancer is a deadly disease with a growing incidence rate, causing over 50,000 deaths  
41 annually in the United States [1]. The 5-year survival rate for this cancer is very low, but it can  
42 increase to over 30% with successful surgical resection [2]. However, one of the most serious

43 complications of pancreatic surgery is the development of postoperative pancreatic fistulas  
44 (POPF) or leaks, which can occur in up to 1 in 3 patients [3]. The impact of POPF on patients is  
45 twofold; it not only increases immediate postoperative complications but also adversely affects  
46 medium to long-term oncological outcomes. POPF increases postoperative mortality because of  
47 prolonged hospital stays and higher reoperation rates [4]. In addition, POPF is also linked to  
48 worse oncological outcomes for patients, notably tumor recurrence and overall survival [5,6].

49 Current fistula risk prediction models do not include modifiable intraoperative risk factors for  
50 mitigating pancreatic fistula [7]. The poorly perfused surgical neck of the pancreas, vulnerable to  
51 ischemia, is a known key factor in developing leaks [8,9]. Indocyanine green (ICG) fluorescence  
52 is used to assess tissue perfusion during surgery, but its effectiveness in predicting pancreatic  
53 leaks has yet to be systematically studied. A reliable intraoperative method to analyze blood  
54 perfusion could help guide surgical margins and reduce the risk of pancreaticojejunostomy leaks,  
55 ultimately improving patient outcomes.

56 Indocyanine green (ICG) is an FDA-approved dye that emits fluorescence when near-infrared  
57 light is applied, making it useful for visualizing tissue perfusion during surgery. ICG is injected  
58 intravenously, traveling to tissues via arteries. While ICG is now considered standard in some  
59 surgical disciplines, it currently needs to be widely used in pancreatic surgery, primarily due to a  
60 lack of adequately powered prospective studies analyzing the benefits of its use and surgeons  
61 wanting more evidence to change their practices [10]. Regarding pancreatic surgery, ICG is  
62 mostly used for anatomical identification of structures to improve surgical safety, avoid damage  
63 to critical structures, and delineate tumors for excision [11–13].

64 In pancreatic surgery, ICG has been used to visualize tissue blood perfusion, with recent studies  
65 showing promising results [13,14]. Pancreatic surgeons have shown interest in further studies on

66 ICG for better visualization of tissue perfusion. A recently published Delphi consensus study  
67 reported that almost 80% of experts agreed on the need to focus research efforts of ICG in  
68 predicting the risk for POPF [10]. Although research on ICG for evaluating leaks after  
69 pancreatectomy is limited, one study showed its potential for detecting leaks in a single patient  
70 retrospectively [13]. ICG has shown potential benefits in improving visualization and outcomes  
71 in pancreas surgery. Moreover, ICG has an excellent safety profile, with Clavien-Dindo grade  $\geq 4$   
72 complications occurring in only 0.05% of cases where it is utilized [15]. Long-term potential  
73 benefits include correlating ICG uptake with pancreatic remnant perfusion and providing critical  
74 information for clinical decisions to avoid POPFs.

75 This study protocol aims to investigate the relationship between hypoperfusion during surgery  
76 and the development of postoperative leaks to identify modifiable intraoperative interventions to  
77 decrease leak rates. The goal is to leverage the potential positive outcomes from this study to  
78 design a phase III clinical trial to evaluate improving remnant gland perfusion and potentially  
79 decreasing complications.

## 80 **Materials and methods**

81 This protocol is for a Phase II, open-label, surgeon-blinded, observational study to assess the  
82 predictive potential of intraoperative perfusion parameters at the pancreatic cut edge via ICG and  
83 its relation to fistula formation versus conventional measurements. The study design consists of a  
84 single-arm intervention group at a single academic center: the Oregon Health & Science  
85 University Hospital in the United States. Following international and national definitions, this  
86 center is considered a high-volume hospital for pancreatectomies [16,17].

87 This study protocol adheres to the SPIRIT guidelines for trial reporting [18]. To ensure adequate  
88 representation of ethnic and racial group demographics in the study, a full consent form and  
89 protocol will be available for English- and Spanish-speaking participants. Short summaries of the  
90 consent forms are available in other languages. Consent will be obtained by members of the  
91 surgical department, including clinical staff and research assistants. This clinical trial is  
92 registered in ClinicalTrials.gov with the ID NCT06084013.

### 93 **Sample size**

94 Given the limited data of ICG perfusion in the pancreas, the sample size calculation was based  
95 on determining a detectable difference between the fistula and no fistula groups. Anticipating  
96 balanced numbers between the two groups, our sample size of 50 participants will have 80%  
97 power to detect at least a 25% difference in a leak or fistula rate, assuming a 20% leak rate for a  
98 normal ICG perfusion group. We account for a liberal exclusion of 30% of participants due to  
99 multiple and complex postoperative factors known to be associated with leaks. Therefore, we  
100 anticipate screening 75 participants and enrolling 50.

### 101 **Eligibility Criteria**

102 All participants must fulfill eligibility criteria and have none of the excluding criteria.

103 Inclusion Criteria:

- 104 1. Participant scheduled for pancreaticoduodenectomy for any diagnosis.
- 105 2. Participants  $\geq$  18 years of age.
- 106 3. Ability to understand the nature and individual consequences of clinical trials.
- 107 4. Written informed consent from the participant or legally authorized representative.

- 108 5. For participants of childbearing potential, a negative pregnancy test and adequate  
109 contraception until 14 days after the trial intervention.
- 110 6. Participant needs to have an operative drain (any closed suction drain) after the  
111 procedure.
- 112 7. Participants that do not require arterial reconstruction.
- 113 8. Participants that require minor portal venous reconstruction including patch venoplasty.

114 Exclusion Criteria:

- 115 1. Patients with previous history of adverse reaction to contrast dye, ICG or components of  
116 the dye.
- 117 2. Prior pancreatectomy.
- 118 3. Known diagnosis of hepatic insufficiency, hepatitis, liver fibrosis or cirrhosis, or chronic  
119 pancreatitis.
- 120 4. Because this study focuses on hypoperfusion, patients will be excluded if in postoperative  
121 day 3-5 had any of the following: persistent SBP <90 mmHg unresponsive to 1L  
122 crystalloid, unexpected ICU transfer, blood transfusion of >2 units intraoperatively or 1  
123 postoperatively, continuous vasopressor treatment or ACLS protocol initiation.
- 124 5. Organ failure, anuria or NSQIP-identified complication will be reviewed by PI and  
125 attending surgeon and decide exclusion.
- 126 6. Patients that require arterial reconstruction as part of their procedures.

127 **Blinding**

128 To avoid the influence of ICG measurements on surgical decisions at this stage of the trial, this  
129 study will involve surgeon-blinding. During intraoperative measurements, the primary surgeon

130 must either step outside the operating room or be positioned to avoid a line of sight to the  
131 imaging device monitor. The secondary surgeon will remain scrubbed in for this portion of the  
132 case. Both study personnel and operating room staff will ensure this blinding process is  
133 successful. Any instances of the surgeon viewing the measurements will result in the  
134 participant's removal from the study. To ensure adequate surgeon-blinding, objective  
135 measurements of the captured images are performed postoperatively, with no relay of this  
136 information to the surgeons during the 30 days of the active study phase. Since this study is  
137 open-label, participants will know if they received the dye and underwent intraoperative  
138 measurements. As this intervention is not standard of care, there is no need for premature  
139 unblinding to the surgeons. Imaging measurements will only be available to surgeons and  
140 participants after the end of the study follow-up, which is 30 days after surgery.

## 141 **Intervention**

142 During pancreatectomy, after the surgical specimen is removed and before creating the  
143 pancreatojejunostomy anastomosis, a single dose of 12.5 mg (5mL once reconstituted) of ICG  
144 will be administered intravenously by the anesthesiologist or certified nurse anesthetist. Spy+  
145 Elite (Stryker, USA) will be used to record perfusion metrics, taking as reference the gastric  
146 body and small intestine to compare differences in perfusion of the pancreatic stump. Recording  
147 of a video image starts as soon as the dye is injected. Still pictures will be extracted from the  
148 video at 10-second intervals once tissue saturation is stable, allowing a comparison of perfusion  
149 to the pancreatic stump and the reference tissue.

150 While measurements and recording of perfusion are being obtained, the primary surgeon will  
151 step out of the operating room to ensure that ICG-derived data does not influence the surgical

152 plan. Upon the study's completion, descriptive statistics will be reported to analyze the impact of  
153 ICG use and perfusion measurements on pancreatic surgeries. During ICG administration, vital  
154 signs will be continuously monitored, and hypersensitivity symptoms will be managed promptly.  
155 An intra-abdominal drainage tube will be placed to assess for amylase levels.  
  
156 Participants can withdraw consent at any time. Adverse effects from the study interventions will  
157 be monitored and reported to institutional authorities. Figure 1 shows the schedule for  
158 participants.

159 **Figure 1.** SPIRIT Schedule of Enrollment Interventions and Assessments  
160

## 161 **Outcomes**

### 162 **Intraoperative**

163 During the surgery, a 90-120-second video will be captured to analyze ICG perfusion metrics.  
164 Because no current gold-standard metric exists for this imaging technique in the pancreas,  
165 several metrics will be analyzed. Quantitative ICG metrics will include absolute and relative ROI  
166 scores within the Cinevaq (Stryker, USA) software, T0 (the time from ICG injection until the  
167 first fluorescent signal), TMax (time from the first ICG signal until maximum uptake is  
168 achieved), as well as ingress and egress rates for the contrast [19,20].

### 169 **Postoperative**

170 After the surgery, the participant would enter the study's follow-up period. The main outcome  
171 will be the development or absence of postoperative pancreatic fistula, as defined by the most  
172 updated definition of the International Study Group in Pancreatic Surgery (ISGPS) [21].

173 Following this, we will collect surgical drain amylase levels in the first three days after surgery,  
174 clinical conditions of the participant, imaging results, and persistent drainage from the drain,  
175 among other factors delineated in the ISGPS. Figure 2 depicts a flowchart for individual  
176 participants in the trial.

177 **Figure 2. Trial Flowchart.** Flowchart for participants in the VIPR-1 trial.

178 Descriptive statistics will be used to compare patients that developed postoperative fistula. ICG  
179 metrics will then be compared with multivariable modeling to study the impact they might have  
180 on postoperative fistulas.

181 Because there are characteristics that might influence development of POPF, the following  
182 participant and case characteristics will be recorded and analyzed as covariates affecting  
183 outcomes: 1) type of pancreatectomy, 2) principal surgeon, 3) operative length, 4) blood loss in  
184 mL, 5) intraoperative blood transfusion, 6) duct size in mm, 7) gland texture, 8) intraoperative  
185 use of vasopressors, 9) race, 10) BMI, 11) age, 12) neoadjuvant therapy and 13) vascular  
186 reconstruction [22].

## 187 **Data management**

188 Data to be collected includes baseline participant demographics relevant to our study, including  
189 sex, age, ethnicity, race, height, weight, ECOG performance status, disease stage at study entry,  
190 cancer therapy and biomarker status.

191 Collected data will be stored in a trial-specific database that lives in an encrypted cloud service  
192 that is institutionally compliant. Here, participant-level information will be captured without any  
193 of the 18 HIPPA identifiers; a participant key will be stored separately and securely. This study

194 will comply with the Data and Safety Monitoring Plan established by the Knight Clinical  
195 Research Quality & Administration.

## 196 **Safety considerations**

197 There are two relevant safety considerations for this study. The first involves safety during the  
198 imaging procedure, and the second involves securing participant data. ICG is considered a  
199 relatively inert contrast agent compared to other more commonly used imaging agents. The most  
200 frequently encountered adverse effects of ICG injection include allergic-type reactions,  
201 presenting as nausea and urticaria, with life-threatening complications such as anaphylactic  
202 shock being rare (<0.05%) [23]. Participants are made aware of the potential consequences of  
203 ICG injection at the time of screening and consent.

204 All adverse effects are reported within 24 hours through the Clinical Trials Management System,  
205 connected to ClinicalTrials.gov. The Knight Cancer Institute, as the trial sponsors, performs  
206 constant auditing on a participant-level basis. Participant information will be kept secure by  
207 restricting access to direct study personnel, and all images and captured participant-level data  
208 will be kept in encrypted platforms.

## 209 **Ethical considerations**

210 The VIPR-1 trial follows guidelines set out by the Declaration of Helsinki [24]. The trial  
211 underwent review and subsequent approval from the Knight Cancer Research Institute via the  
212 Clinical Research and Review Committee on 9/2023 and then the Institutional Review Board  
213 from Oregon Health and Science University on 11/2023.

## 214 **Status and timeline**

215 The VIPR-1 trial is registered in the ClinicalTrials government platform [25]. Participant  
216 recruitment started on 06/10/2024, and the estimated finishing time is one year after the first  
217 patient enrollment. Any updates to the protocol will be informed in the trial registry platform and  
218 the protocol itself. After the trial is completed, we intend to publish our results in a scientific  
219 journal.

## 220 **Discussion**

221 This is the first prospective clinical trial in the United States to evaluate pancreatic remnant  
222 perfusion using ICG to predict fistulas and leaks. A recently published systematic review  
223 compiled all reports of the use of pancreatic remnant perfusion intraoperatively. A total of 5  
224 studies were found, and only two were prospective [26]. The first prospective trial used ICG for  
225 postoperative acute pancreatitis rather than POPF as a primary outcome measure, where  
226 adequate statistical power for POPF was not mentioned [14]. The other prospective trial looked  
227 at subjective descriptions of adequate blood flow to the pancreatic remnant to characterize  
228 hypoperfusion and guide margins [27]. Thus, further highlighting the need for prospective  
229 intraoperative and subjective evaluation of perfusion. While studies have reported that  
230 hypoperfusion detected by ICG is correlated with POPF, currently, no cutoff for considering  
231 adequate or inadequate perfusion exists. After operative measurements are performed, we intend  
232 to utilize the Cinevaq software (Stryker, USA) to measure the perfusion difference with  
233 reference to gastrointestinal tissue and within the pancreas. If a correlation between perfusion  
234 and leaks is detected, we will perform statistical analysis at different thresholds for poor  
235 perfusion to identify the best cutoff delta in perfusion to predict POPF. A recent study  
236 demonstrated that cutoff values for hypoperfusion in breast tissue do not translate between

237 different imaging systems. Specifically, a 33% relative perfusion measurement has been  
238 validated in breast tissue, specifically in the SPY-Elite® platform. However, on the newer SPY-  
239 PHI platform, the same cutoff value did not correlate with hypoperfusion [28]. While studies like  
240 this are not available in pancreatic tissue, it is possible that a specific cutoff would need to be  
241 validated for each type of device model in pancreatic perfusion dynamics.

242 If the results are positive, a phase III study can be designed to evaluate whether ICG metrics can  
243 guide surgical margins to optimize perfusion of the pancreatic remnant and decrease POPF. The  
244 level of the transection of the neck of the pancreas has been previously characterized as  
245 important for POPF risk [29]. Capturing patient preoperative and intraoperative variables is  
246 crucial to adjust for possible confounders in perfusion observations and the development of  
247 POPF. All patients undergoing open pancreatectomy for any diagnosis will be screened for this  
248 study. Broad inclusion and exclusion criteria will be implemented to ensure a diverse group of  
249 patients and reach the sample size needed.

250 In the past decade, minimally invasive pancreatectomy has gained major interest, as evidenced  
251 by numerous studies examining ways to reduce postoperative complications. Current data are  
252 inconclusive regarding the impact of surgical technique (open versus minimally invasive) on  
253 POPF rates, with some studies suggesting benefits. In contrast, others indicate an increased risk  
254 of this outcome with minimally invasive surgery [16,30]. A recent proof of concept prospective  
255 study investigated the predictive potential of ICG in determining suture tension-induced  
256 hypoperfusion in pancreatic reconstruction. In this study, hypoperfusion to the pancreas by ICG  
257 was more frequently encountered in those patients who developed fistulas [31]. This study,  
258 however, was performed only in robotic cases, and all measurements were taken after the

259 surgeon placed sutures for the anastomosis. We intend to measure perfusion before the pancreas  
260 is sutured to the jejunum to measure the complete surface of the remnant to be anastomosed.  
261 Pancreatectomies are among the most challenging and lengthy procedures in gastrointestinal  
262 surgery. Because of this, the trial's impact on time added to the case should be minimal.  
263 Increases in operative time elevate costs and staff utilization and are associated with surgical  
264 complications in pancreatic surgery [32]. To address this, the operative time will be compared to  
265 control cases that did not undergo ICG measurements. This comparison will determine the  
266 impact of ICG measurements on total operative time. Studies in other gastrointestinal surgeries  
267 using ICG have shown a potential increase in operative time by 10-15 minutes, but this increase  
268 has not been statistically significant [33]. We currently do not know the impact of ICG in open  
269 pancreatectomies. ICG is now standard in many gastrointestinal procedures but not for the  
270 pancreas. We intend to record and subsequently report the effect of ICG on operative time for  
271 pancreatectomies.

272 The main limitation of this study is that our findings might not be generalizable to other  
273 institutions because of inherent differences in practice standards, surgeon experience, and  
274 imaging devices used.

275 In conclusion, POPF is highly prevalent in pancreatectomy. Current predictive measures to  
276 detect POPF intraoperatively have not been successful in decreasing complication rates. ICG  
277 perfusion of the pancreatic edge could potentially allow surgeons to predict POPF. We aim to  
278 investigate this further with the VIPR-1 trial.

279

280 **Authors Contributions - CRediT author statement**

281 GSG: Writing- Original Draft Preparation, Methodology. AW: Writing- Original draft  
282 preparation, FGR: Writing- Reviewing and Editing, SCM: Visualization, Writing- Reviewing  
283 and Editing, BCS: Visualization, Writing- Reviewing and Editing, PJW: Conceptualization,  
284 Methodology, Writing – Original draft, Funding Acquisition, Project Administration.

## 285 **Acknowledgments**

286 None.

## 287 **Supporting information**

288 S1 Fig. **SPIRIT Checklist.**

## 289 **References**

- 290 1. Cancer Facts & Figures 2023 [Internet]. [cited 2024 Apr 9]. Available from:  
291 [https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/2023-cancer-](https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/2023-cancer-facts-figures.html)  
292 [facts-figures.html](https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/2023-cancer-facts-figures.html)
- 293 2. Strobel O, Lorenz P, Hinz U, Gaida M, König AK, Hank T, et al. Actual Five-year  
294 Survival After Upfront Resection for Pancreatic Ductal Adenocarcinoma: Who Beats the Odds?  
295 *Ann Surg.* 2022 May 1;275(5):962–71.
- 296 3. Malgras B, Dokmak S, Aussilhou B, Pocard M, Sauvanet A. Management of  
297 postoperative pancreatic fistula after pancreaticoduodenectomy. *J Visc Surg.* 2023 Feb  
298 1;160(1):39–51.
- 299 4. Torres OJM, Moraes-Junior JMA, Fernandes EDSM, Hackert T. Surgical Management of  
300 Postoperative Grade C Pancreatic Fistula following Pancreatoduodenectomy. *Visc Med.*  
301 2022;38(4):233–42.
- 302 5. Dhayat SA, Tamim ANJ, Jacob M, Ebeling G, Kerschke L, Kabar I, et al. Postoperative  
303 pancreatic fistula affects recurrence-free survival of pancreatic cancer patients. Chen RJ, editor.  
304 *PLOS ONE.* 2021 Jun 4;16(6):e0252727.
- 305 6. Bonaroti JW, Zenati MS, Al-abbas AI, Rieser CJ, Zureikat AH, Hogg ME, et al. Impact  
306 of postoperative pancreatic fistula on long-term oncologic outcomes after pancreatic resection.  
307 *HPB.* 2021 Aug;23(8):1269–76.

- 308 7. Callery MP, Pratt WB, Kent TS, Chaikof EL, Vollmer CM. A Prospectively Validated  
309 Clinical Risk Score Accurately Predicts Pancreatic Fistula after Pancreatoduodenectomy. *J Am*  
310 *Coll Surg*. 2013 Jan;216(1):1–14.
- 311 8. Nahm CB, Brown KM, Townend PJ, Colvin E, Howell VM, Gill AJ, et al. Acinar cell  
312 density at the pancreatic resection margin is associated with post-pancreatectomy pancreatitis  
313 and the development of postoperative pancreatic fistula. *HPB*. 2018 May;20(5):432–40.
- 314 9. Nahm CB, Connor SJ, Samra JS, Mittal A. Postoperative pancreatic fistula: a review of  
315 traditional and emerging concepts. *Clin Exp Gastroenterol*. 2018 Mar 15;11:105–18.
- 316 10. De Muynck LDAN, White KP, Alseidi A, Bannone E, Boni L, Bouvet M, et al.  
317 Consensus Statement on the Use of Near-Infrared Fluorescence Imaging during Pancreatic  
318 Cancer Surgery Based on a Delphi Study: Surgeons’ Perspectives on Current Use and Future  
319 Recommendations. *Cancers*. 2023 Jan 20;15(3):652.
- 320 11. Newton AD, Predina JD, Shin MH, Frenzel-Sulyok LG, Vollmer CM, Drebin JA, et al.  
321 Intraoperative Near-infrared Imaging Can Identify Neoplasms and Aid in Real-time Margin  
322 Assessment During Pancreatic Resection. *Ann Surg*. 2019 Jul;270(1):12–20.
- 323 12. Asbun D, Kunzler F, Marin R, Asbun HJ. Pancreatic fluorescence using continuous  
324 indocyanine green infusion. *J Surg Oncol*. 2022 Dec;126(7):1215–8.
- 325 13. Rho SY, Kim SH, Kang CM, Lee WJ. Is ICG-enhanced image able to help predicting  
326 pancreatic fistula in laparoscopic pancreaticoduodenectomy? *Minim Invasive Ther Allied*  
327 *Technol MITAT Off J Soc Minim Invasive Ther*. 2019 Feb;28(1):29–32.
- 328 14. Doussot A, Decrock M, Calame P, Georges P, Turco C, Lakkis Z, et al. Fluorescence-  
329 based pancreas stump perfusion is associated with postoperative acute pancreatitis after  
330 pancreatoduodenectomy a prospective cohort study. *Pancreatol Off J Int Assoc Pancreatol IAP*  
331 *Al*. 2021 May 18;S1424-3903(21)00161-7.
- 332 15. Hope-Ross M, Yannuzzi LA, Gragoudas ES, Guyer DR, Slakter JS, Sorenson JA, et al.  
333 Adverse Reactions due to Indocyanine Green. *Ophthalmology*. 1994 Mar;101(3):529–33.
- 334 16. Panni RZ, Panni UY, Liu J, Williams GA, Fields RC, Sanford DE, et al. Re-defining a  
335 high volume center for pancreaticoduodenectomy. *HPB*. 2021 May;23(5):733–8.
- 336 17. El Amrani M, Clément G, Lenne X, Laueriere C, Turpin A, Theis D, et al. Should all  
337 pancreatic surgery be centralized regardless of patients’ comorbidity? *HPB*. 2020  
338 Jul;22(7):1057–66.
- 339 18. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al.  
340 SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials. *Ann Intern Med*.  
341 2013 Feb 5;158(3):200.
- 342 19. Oppermann C, Dohrn N, Pardes HY, Klein MF, Eriksen T, Gögenur I. Real time organ  
343 hypoperfusion detection using Indocyanine Green in a piglet model. *Surg Endosc* [Internet].

- 344 2024 Jun 13 [cited 2024 Jul 15]; Available from: [https://link.springer.com/10.1007/s00464-024-](https://link.springer.com/10.1007/s00464-024-10938-0)  
345 10938-0
- 346 20. Iwamoto H, Matsuda K, Hayami S, Tamura K, Mitani Y, Mizumoto Y, et al. Quantitative  
347 Indocyanine Green Fluorescence Imaging Used to Predict Anastomotic Leakage Focused on  
348 Rectal Stump During Laparoscopic Anterior Resection. *J Laparoendosc Adv Surg Tech*. 2020  
349 May 1;30(5):542–6.
- 350 21. Bassi C, Marchegiani G, Dervenis C, Sarr M, Abu Hilal M, Adham M, et al. The 2016  
351 update of the International Study Group (ISGPS) definition and grading of postoperative  
352 pancreatic fistula: 11 Years After. *Surgery*. 2017 Mar;161(3):584–91.
- 353 22. Schuh F, Mihaljevic AL, Probst P, Trudeau MT, Müller PC, Marchegiani G, et al. A  
354 Simple Classification of Pancreatic Duct Size and Texture Predicts Postoperative Pancreatic  
355 Fistula: A classification of the International Study Group of Pancreatic Surgery. *Ann Surg*. 2023  
356 Mar;277(3):e597.
- 357 23. Obana A, Miki T, Hayashi K, Takeda M, Kawamura A, Mutoh T, et al. Survey of  
358 Complications of Indocyanine Green Angiography in Japan. *Am J Ophthalmol*. 1994  
359 Dec;118(6):749–53.
- 360 24. World Medical Association Declaration of Helsinki: Ethical Principles for Medical  
361 Research Involving Human Subjects. *JAMA*. 2013 Nov 27;310(20):2191.
- 362 25. Worth PJ. Assessing the Role of Intraoperative Indocyanine Green Perfusion of the  
363 Transected Pancreas in Predicting Postoperative Pancreatic Leaks [Internet]. *clinicaltrials.gov*;  
364 2024 Mar [cited 2023 Dec 31]. Report No.: NCT06084013. Available from:  
365 <https://clinicaltrials.gov/study/NCT06084013>
- 366 26. Robertson FP, Spiers HVM, Lim WB, Loveday B, Roberts K, Pandanaboyana S.  
367 Intraoperative pancreas stump perfusion assessment during pancreaticoduodenectomy: A  
368 systematic scoping review. *World J Gastrointest Surg*. 2023 Aug 27;15(8):1799–807.
- 369 27. Strasberg SM, Drebin JA, Mokadam NA, Green DW, Jones KL, Ehlers JP, et al.  
370 Prospective Trial of a Blood Supply-Based Technique of Pancreaticojejunostomy: Effect on  
371 Anastomotic Failure in the Whipple Procedure1. *J Am Coll Surg*. 2002 Jun;194(6):746–58.
- 372 28. Lauritzen E, Bredgaard R, Bonde C, Jensen LT, Damsgaard TE. An observational study  
373 comparing the SPY-Elite® vs. the SPY-PHI QP system in breast reconstructive surgery. *Ann*  
374 *Breast Surg*. 2023 Jun;7:12–12.
- 375 29. Bardol T, Delicque J, Hermida M, Herrero A, Guiu B, Fabre JM, et al. Neck transection  
376 level and postoperative pancreatic fistula after pancreaticoduodenectomy: A retrospective cohort  
377 study of 195 patients. *Int J Surg*. 2020 Oct;82:43–50.
- 378 30. Uijterwijk BA, Kasai M, Lemmers DHL, Chinnusamy P, Van Hilst J, Ielpo B, et al. The  
379 clinical implication of minimally invasive versus open pancreatoduodenectomy for non-

380 pancreatic periampullary cancer: a systematic review and individual patient data meta-analysis.  
381 *Langenbecks Arch Surg.* 2023 Aug 15;408(1):311.

382 31. Chen JW, Lof S, Zwart MJW, Busch OR, Daams F, Festen S, et al. Intraoperative  
383 Fluorescence Imaging During Robotic Pancreatoduodenectomy to Detect Suture-Induced  
384 Hypoperfusion of the Pancreatic Stump as a Predictor of Postoperative Pancreatic Fistula  
385 (FLUOPAN): Prospective Proof-of-concept Study. *Ann Surg Open.* 2023 Dec;4(4):e354.

386 32. Williams MD, Bhama AR, Naffouje S, Kamarajah SK, Becerra AZ, Zhang Y, et al.  
387 Effect of Operative Time on Outcomes of Minimally Invasive Versus Open  
388 Pancreatoduodenectomy. *J Gastrointest Surg.* 2023 Jan;27(1):93–104.

389 33. Cassinotti E, Al-Taher M, Antoniou SA, Arezzo A, Baldari L, Boni L, et al. European  
390 Association for Endoscopic Surgery (EAES) consensus on Indocyanine Green (ICG)  
391 fluorescence-guided surgery. *Surg Endosc.* 2023 Mar;37(3):1629–48.

392

393

	STUDY PERIOD					
	Screening	Post-intervention (days)				End of follow up
TIMEPOINT (days)	-1	0	D <sub>1</sub>	D <sub>2-7</sub>	D <sub>7-29</sub>	D <sub>30</sub>
<b>ENROLLMENT:</b>	X					
<b>Eligibility screen</b>	X					
<b>Informed consent</b>	X					
<b>INTERVENTIONS:</b>						
<i>Routine Pancreatectomy</i>			X			
<i>Intraoperative imaging</i>			X			
<b>ASSESSMENTS:</b>						
<i>Health status, medical history, allergies</i>		X				
<i>Tumor size, pathology results</i>		X			X	
<i>Drain amylase</i>				X		
<i>Signs and symptoms for fistula</i>			X	X	X	
<i>Postoperative imaging if fistula suspicion</i>			X	X	X	
<i>Primary outcome final assessment</i>						X

medRxiv preprint doi: <https://doi.org/10.1101/2024.09.13.24313603>; this version posted September 14, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 1




Figure 2